



Patient ID SA00139394	Patient Name VALIDATIONRNV, DLL3	Birth Date 1950-03-10	Gender F	Age 70
Order Number SA00139394	Client Order Number SA00139394	Ordering Physician CLIENT,CLIENT	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 25 Sep 2020 13:00		

DLL3(SP347)Semi-Quant IHC,Manual

Case Number CR-20-1096

Interpretation

MCR

Lung, Left Lower Lobe, specimen for DLL3 immunohistochemistry studies (clone SP347, Ventana Medical Systems Inc, Tucson, AZ) (XS-20-1234-A1):

75% tumor cells are positive for DLL3.

Interpretation: Preliminary studies suggest that DLL3 expression may predict benefit from therapy with DLL3-targeted antibody-drug conjugate. This result should not be used as the sole factor in determining treatment, as other factors (for example, tumor mutation burden, and microsatellite instability) have also been studied as predictive markers.

Fixation: This test has been validated for non-decalcified paraffin embedded tissue specimens fixed in 10% neutral buffered formalin. This assay has not been validated on tissues subjected to the decalcification process and/or use of alternative fixatives for bone/bone marrow specimens or cell blocks.

Material Received

MCR

Report electronically signed by

MCR

A. XS-20-1234: Lung, Left Lower Lobe
1 block

Jennifer Pettengill

Disclaimer

MCR

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Received: 28 Sep 2020 07:58

Reported: 29 Sep 2020 14:20

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	William G. Morice M.D. Ph.D	24D0404292